

PUREVAX® Recombinant FeLV.

Pure, proven protection.



Feline leukemia virus (FeLV) is contagious, lethal and incurable.

FeLV can lead to the development of cancer in up to 30% of persistently infected cats and can suppress the immune system and bone marrow function, resulting in additional infectious diseases or anemia.¹

“Recombinant technology allowed the development of a new generation of targeted vaccines, combining a high level of safety and efficacy for today’s small animal practice.”

—Richard B. Ford, DVM, MS, DACVIM, DACVPM (Hon), Professor of Medicine, College of Veterinary Medicine, North Carolina State University



Unique technology makes the difference.

PUREVAX Recombinant FeLV vaccine:

- Is the only nonadjuvanted feline leukemia vaccine
- Uses advanced recombinant canarypox-vectored vaccine technology
- Comprehensive immune response²
- Is available as a convenient injectable

Adjuvants can present potential risks to feline patients.^{2,3}

- Injection site reaction
- Injection site granuloma
- Chronic inflammation

With the strong immune response provided by its unique technology, PUREVAX Recombinant FeLV vaccine needs no adjuvant.

Because of this ...	You and your patients benefit this way ...
No adjuvant	Reduces the risks associated with adjuvants, including injection site reaction ⁴ injection site granuloma ⁴ or chronic inflammation ^{2,3} potentially caused by adjuvants ²
Recombinant canarypox-vectored technology	Comprehensive immune response; no need for an adjuvant ⁴
Humoral and cell-mediated immunity ²	Rapid, comprehensive immune response
Available in injectable form	Convenience of injectable vaccine with the assurance of quality vaccine
Approved for kittens as young as 8 weeks of age ⁵	Added assurance for family and pet

Feline Guarantee

Merial is committed to supporting the use of nonadjuvanted vaccines in feline patients, throughout their life. We understand, however, that patients sometimes move, or are otherwise lost to observation, making it impossible to verify their complete vaccination history. Our PUREVAX[®] Guarantee therefore falls into three tiers:

Diagnosis	In the rare event that a cat is definitively diagnosed with an injection-site sarcoma:			
	Guarantee Tier	Tier 1	Tier 2	Tier 3
Criteria		AND if that feline patient has been exclusively vaccinated with PUREVAX nonadjuvanted feline vaccines over its entire lifetime,	AND if that feline patient has been exclusively vaccinated with PUREVAX during the most recent 5 years of their life,	AND if that feline patient's LAST vaccination was with a PUREVAX nonadjuvanted feline vaccine but the patient does not otherwise have a documented history of PUREVAX-only vaccination,
Support		Merial will support standard and reasonable diagnostic and treatment costs up to \$5,000.	Merial will support standard and reasonable diagnostic and treatment costs up to \$3,000.	Merial will support standard and reasonable diagnostic and treatment costs up to \$1,500.

Other Adverse Events and Lack of Efficacy

Merial also provides customer support in the rare event that feline patients experience other types of adverse events or contract the disease for which they are vaccinated. Please contact our VTS representatives at 1-888-637-4251 (Option 3) for assistance in determining support eligibility in these instances.

The only nonadjuvanted feline leukemia vaccine helps protect vulnerable kittens and cats.

PUREVAX Recombinant FeLV product label description.⁵

PUREVAX Recombinant FeLV contains a nonadjuvanted lyophilized suspension of a recombinant vectored feline leukemia vaccine plus sterile water diluent. A canarypox vector has been modified, using recombinant technology, to produce expression of desired antigens capable of stimulating a protective immune response to feline leukemia. Safety and immunogenicity of this product have been demonstrated by vaccination and challenge tests in susceptible cats.

Indications

PUREVAX Recombinant FeLV is recommended for the vaccination of healthy cats 8 weeks of age or older as an aid in the prevention of disease due to feline leukemia virus.

Dosage

Aseptically rehydrate the lyophilized vaccine with 1 ml of the accompanying sterile water diluent, and agitate. Administer 1 ml (1 dose) subcutaneously. For primary vaccination, cats should receive two 1-ml dose vaccinations, three weeks apart. Annual revaccination is recommended. Diagnostic testing for FeLV prior to vaccination is recommended.

Precautions

Store at 2-8°C (35-46°F). Burn container and all unused contents. Contains gentamicin as a preservative. It is generally recommended to avoid vaccination of pregnant cats. In rare instances, administration of vaccines may cause lethargy, fever, and inflammatory or hypersensitivity types of reactions.

Treatment may include antihistamines, anti-inflammatories, and/or epinephrine.



To learn more about PUREVAX vaccines and how they can benefit your patients, contact your Sales Representative or your Distributor Representative or Call Merial Customer Care: 1-888-Merial-1 or Visit MERIALconnect.comSM

Ask your Representative about our Satisfaction Guarantee for PUREVAX.

Merial is now part of Boehringer Ingelheim.

PUREVAX[®] is a registered trademark, and MERIALconnect.comSM is a service mark, of Merial. ©2017 Merial, Inc., Duluth, GA. All rights reserved. PURE15DETAILERS 1 (11/17).

¹ *The Merck Veterinary Manual*, 10th ed. 2010:718-722.

² Greene CE, Schultz RD. Immunoprophylaxis. In: Greene, CE, ed. *Infectious Diseases of the Dog and Cat*. 4th ed. St Louis, MO: Elsevier Saunders., 2012:1163-1205.

³ Day MJ, Schoon H-A, Magnol J-P, et al. A kinetic study of histopathological changes in the subcutis of cats injected with non-adjuvanted and adjuvanted multi-component vaccines. *Vaccine*. 2007; 25:4073-4084.

⁴ Macy DW. The Potential Role and Mechanisms of FeLV Vaccine-Induced Neoplasms. *Seminars in Vet Medicine and Surgery (Small Animal)* 1995;10(4):234-237.

⁵ PUREVAX Recombinant FeLV product label.